Instrument Inactif

Communiqués Aytu Bioscience Inc OTC Bulletin Board

Actions

AYTU

US0547542052

Produits pharmaceutiques

Cours en clôture OTC Bulletin Board
- ^USD	-

23/09	Transcript : Aytu BioPharma, Inc., Q4 2026 Earnings Call, Sep 22, 2026
22/09	Aytu BioPharma, Inc. publie ses résultats pour l’exercice clos le 30 juin 2026	CI

Communiqués

22/09	Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results	AQ
16/09	Aytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026	AQ
01/06	Aytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026	AQ
18/05	Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026	AQ
13/05	Aytu BioPharma : Corporate Presentation May 2026 View Presentation Investor Day January 2026 View Presentation	PU
13/05	Aytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial Results	AQ
06/05	Aytu BioPharma to Report Fiscal 2026 Third Quarter Operational and Financial Results on May 13, 2026	AQ
03/04	Aytu BioPharma : Corporate Presentation April 2026 View Presentation Investor Day January 2026 View Presentation	PU
17/03	Aytu BioPharma : Corporate Presentation March 2026 View Presentation Investor Day January 2026 View Presentation	PU
04/02	Aytu BioPharma : Corporate Presentation February 2026 View Presentation Investor Day January 2026 View Presentation	PU
03/02	Aytu BioPharma : Reports Fiscal 2026 Second Quarter Operational and Financial Results	PU
20/01	Aytu BioPharma : Recaps Investor Day Held on January 20, 2026	PU
20/01	Aytu BioPharma : Corporate Presentation January 2026 Investor Day View Presentation	PU
12/01	Aytu BioPharma : Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City	PU
18/11	Aytu BioPharma : Corporate Presentation November 2025 View Presentation	PU
14/10/25	Aytu BioPharma : Corporate Presentation October 2025 View Presentation	PU
07/05/25	Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025	AQ
21/04/25	Aytu BioPharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025	AQ
04/12/24	TO: ALL CURRENT RECORD HOLDERS AND BENEFICIAL OWNERS OF COMMON STOCK OF AYTU BIOPHARMA, INC. (“AYTU” OR THE “COMPANY”) AS OF OCTOBER 9, 2024 (THE “RECORD DATE”) (“CURRENT AYTU SHAREHOLDERS”) Form 8 K	PU
14/11/24	Aytu BioPharma : Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q)	PU
13/11/24	Aytu BioPharma : Reports Fiscal 2025 First Quarter Operational and Financial Results Form 8 K	PU
02/10/24	Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT and Cotempla XR-ODT in Canada	AQ
01/10/24	Aytu BioPharma : Once approved by Health Canada, Adzenys and Cotempla will be the only orally disintegrating, extended release tablets for the treatment of ADHD commercialized in Canada Form 8 K	PU
26/09/24	Aytu BioPharma : Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results Form 8 K	PU
06/08/24	Aytu BioPharma : Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations Form 8 K	PU